Repligen Corp. (NASDAQ:RGEN) has been assigned an average broker rating score of 1.67 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have issued a strong buy rating on the company. Repligen Corp.’s rating score has declined by 11.3% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokerages have set a 1 year consensus target price of $33.67 for the company and are forecasting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also assigned Repligen Corp. an industry rank of 94 out of 265 based on the ratings given to its competitors.
A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Repligen Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. Jefferies Group reiterated a “hold” rating and set a $28.00 price objective on shares of Repligen Corp. in a research report on Monday, June 13th.
Shares of Repligen Corp. (NASDAQ:RGEN) opened at 29.54 on Tuesday. Repligen Corp. has a 12 month low of $20.07 and a 12 month high of $36.00. The stock has a market cap of $998.04 million, a PE ratio of 118.16 and a beta of 1.29. The firm’s 50-day moving average is $31.83 and its 200 day moving average is $27.62.
Repligen Corp. (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.03. Repligen Corp. had a net margin of 8.69% and a return on equity of 10.74%. The business had revenue of $29.20 million for the quarter, compared to analysts’ expectations of $24.75 million. During the same quarter in the previous year, the business posted $0.11 earnings per share. The business’s revenue was up 35.8% compared to the same quarter last year. On average, equities analysts predict that Repligen Corp. will post $0.44 EPS for the current year.
In other news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $32.58, for a total transaction of $87,966.00. Following the completion of the sale, the director now directly owns 9,394 shares of the company’s stock, valued at $306,056.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.30% of the company’s stock.
Several hedge funds have recently modified their holdings of the stock. First Manhattan Co. raised its stake in shares of Repligen Corp. by 42.8% in the first quarter. First Manhattan Co. now owns 14,275 shares of the company’s stock worth $382,000 after buying an additional 4,275 shares in the last quarter. Virginia Retirement System bought a new stake in shares of Repligen Corp. during the first quarter worth about $381,000. TIAA CREF Investment Management LLC raised its stake in shares of Repligen Corp. by 26.3% in the first quarter. TIAA CREF Investment Management LLC now owns 203,734 shares of the company’s stock worth $5,464,000 after buying an additional 42,400 shares in the last quarter. BlackRock Group LTD raised its stake in shares of Repligen Corp. by 6.3% in the first quarter. BlackRock Group LTD now owns 49,515 shares of the company’s stock worth $1,328,000 after buying an additional 2,915 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in shares of Repligen Corp. by 0.7% in the first quarter. BlackRock Fund Advisors now owns 2,457,356 shares of the company’s stock worth $65,906,000 after buying an additional 16,941 shares in the last quarter. 89.38% of the stock is owned by hedge funds and other institutional investors.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.